Cirius Therapeutics to Participate in Upcoming Healthcare Conferences

GRAND RAPIDS, Mich., Oct. 9, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., a developer of innovative therapies for people suffering from diseases caused by insulin resistance, today announced that its executives will be speaking at the following upcoming conferences.

• MOSAiC ¹ taking place October 23-24, 2025  at the French Embassy,  Washington, D.C.
  
  October 24, 1:30 PM ET:  Innovative MOSAIC Trial Protocol with Multi-Organ Composite Endpoint Seeking Approval of Multiple Indications for a Combinatorial Agent
  
  Robert Beardsley, Ph.D., CEO, will present and participate in a panel discussion of potential regulatory approval pathways for therapies like CIR-0602K that impact metabolic outcomes across multiple organs such as heart, kidneys, and liver.

• Obesity Week ² taking place November 4-7 at Georgia World Congress Center in Atlanta, GA.
  
  November 4, 2:15 PM ET:  Azemiglitazone Potassium (0602K) Synergizes with Tirzepatide (TZP) to Remodel Muscle and Adipose
  
  Jerry Colca, Ph.D., CSO, will present new preclinical data on the combination of CIR-0602K and tirzepatide, including synergistic effects on body composition and weight.

^1.  Metabolic multiOrgan Science Accelerating the Innovation in Clinical trials; 
https://mosaic-nash.tmacademy.org/

^2. https://obesityweek.org/

About Cirius

Cirius is a clinical-stage pharmaceutical company focusing on mitochondrial pyruvate carrier (MPC), addressing the metabolic dysfunction that causes insulin resistance and the organ pathologies associated with type 2 diabetes (T2D) and obesity/overweight. Its lead product candidate, CIR-0602K, is a potential best-in-class novel small molecule being developed as a once-daily oral therapy designed to selectively inhibit the mitochondrial target MPC, which plays a central role in selecting mitochondrial energy substrates. MPC inhibition reprograms mitochondrial metabolism, reducing insulin resistance in cells and driving metabolic benefits in organs throughout the body. This markedly improves glycemic control in diabetes, body composition in obesity, liver function and fibrosis in metabolic dysfunction-associated steatohepatitis (MASH), and outcomes in cardiometabolic disorders.

About CIR-0602K

CIR-0602K has completed 7 US clinical trials including a 52-week placebo-controlled Phase 2b study in 392 participants with MASH with and without T2D, and a 28-day placebo-controlled Phase 2a study in 129 participants with T2D. In those clinical studies it markedly lowered HbA1c and insulin levels, and reduced liver injury and MASH – including on top of existing GLP-1 therapy. A pilot clinical study also showed CIR-0602K markedly reduces HbA1c, insulin levels and fat in muscle, and increases muscle metabolic function in people with obesity & T2D. A Phase 2a study in people with type 1 diabetes (T1D) and supported in part by Breakthrough T1D is expected to open 4Q25.

Preclinical studies also demonstrate increased lean muscle mass, strength and metabolic function, together with metabolically beneficial shifts in adipose tissue phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue includes dramatic reduction in adipocyte size and increase in "beiging." Selectively targeting MPC – while avoiding PPAR-γ activation – CIR-0602K harnesses the real-world proven efficacy of 1^st generation insulin sensitizers, such as pioglitazone, but without their side effect concerns.

Directly correcting a major underlying pathophysiology of chronic metabolic disease, CIR-0602K has the potential to become a cornerstone of therapy. Coupling this potent pharmacology with that of the GLP-1s could particularly benefit patients with T2D, obesity/overweight, MASH and other cardiometabolic diseases.

www.CiriusTx.com

Contact:
[email protected]

SOURCE Cirius Therapeutics